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Abstract
Background: Disturbances in adipose tissue glucose uptake may play a role in the 
pathogenesis of type 2 diabetes, yet its examination by 2‐deoxy‐2‐[18F]fluorodeoxy-
glucose ([18F]FDG) PET/CT is challenged by relatively low uptake kinetics. We 
tested the hypothesis that performing [18F]FDG PET/CT during a hypoglycaemic 
clamp would improve adipose tissue tracer uptake to allow specific comparison of 
adipose tissue glucose handling between people with or without type 2 diabetes.
Design: We enrolled participants with or without diabetes who were at least over-
weight, to undergo a hyperinsulinaemic hypoglycaemic clamp or a hyperinsulinae-
mic euglycaemic clamp (n = 5 per group). Tracer uptake was quantified using [18F]
FDG PET/CT.
Results: Hypoglycaemic clamping increased [18F]FDG uptake in visceral adipose 
tissue of healthy participants (P = 0.002). During hypoglycaemia, glucose uptake in 
visceral adipose tissue of type 2 diabetic participants was lower as compared to 
healthy participants (P < 0.0005). No significant differences were observed in skel-
etal muscle, liver or pancreas.
Conclusions: The present findings indicate that [18F]FDG PET/CT during a hypo-
glycaemic clamp provides a promising new research tool to evaluate adipose tissue 
glucose metabolism. Using this method, we observed a specific impairment in vis-
ceral adipose tissue [18F]FDG uptake in type 2 diabetes, suggesting a previously un-
derestimated role for adipose tissue glucose handling in type 2 diabetes.
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1 |  INTRODUCTION
The amount and distribution of adipose tissue (AT) are im-
portant contributing factors in the development of insulin 
resistance and type 2 diabetes.1 While hepatic2 and muscle3 
insulin resistance are generally regarded as the key factors 
in disrupted glucose homeostasis in type 2 diabetes, AT 
glucose handling could also play an important role. AT 
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has been shown to make a considerable contribution to 
insulin‐stimulated glucose uptake from the circulation.4-6 
Furthermore, there is substantial mechanistic evidence for 
impaired insulin‐stimulated glucose uptake in AT in rela-
tion to obesity.7
Several previous studies have used [18F]FDG PET 
during a hyperinsulinaemic euglycaemic clamp to exam-
ine glucose uptake in different AT depots in individuals of 
different metabolic health, but results have not been com-
pletely consistent. Both Oliveira et al8 and Virtanen et al4 
have shown an obesity‐associated decrease in [18F]FDG 
uptake in visceral AT. However, a similar effect in subcu-
taneous AT was only demonstrated by one study4 and not 
by the other.8 In both these studies, [18F]FDG uptake in 
AT was not significantly different between metabolically 
healthy obese participants and obese individuals with type 
2 diabetes.4,8
These studies have used different methods of [18F]FDG 
PET imaging which could in part explain the different re-
sults. However, using 18F‐FDG PET during a hyperinsu-
linaemic euglycaemic clamp to study tracer uptake in AT 
is challenging because of the low uptake values of [18F]
FDG in AT as compared to skeletal muscle. Consequently, 
it is difficult to determine differences in tracer uptake be-
tween different AT depots and between individuals. The 
role of AT in glucose homeostasis could therefore be un-
derestimated. An interesting case was reported in 2011 by 
Hofman et al in which an [18F]FDG PET/CT scan was per-
formed in a healthy lean individual during unintentional 
insulin‐induced hypoglycaemia. Surprisingly, an altered 
biodistribution of the radiopharmaceutical [18F]FDG was 
observed, with a markedly increased uptake in AT, most 
prominently in visceral AT, as compared to the uptake in 
skeletal muscle.9
Performing [18F]FDG PET during a hyperinsulinaemic 
hypoglycaemic clamp could thus stimulate tracer uptake in 
AT and thereby represent a new method to better examine AT 
glucose handling. We hypothesized that this method could 
elucidate differences in AT metabolism associated with type 
2 diabetes, which would remain undetected in previous stud-
ies. In the current study, we therefore performed [18F]FDG 
PET/CT during a hyperinsulinaemic hypoglycaemic clamp in 
overweight or obese people with type 2 diabetes and healthy 
participants matched for BMI, to compare [18F]FDG uptake 
in AT between these groups.
2 |  SUBJECTS AND METHODS
2.1 | Enrolment
We enrolled five participants with type 2 diabetes who were 
at least overweight (BMI > 25 kg/m2) and five BMI‐matched 
individuals without diabetes to undergo a hyperinsulinaemic 
hypoglycaemic clamp. In addition, five nondiabetic partici-
pants, again matched for BMI, underwent a hyperinsulinae-
mic euglycaemic clamp. All people with type 2 diabetes met 
the following inclusion criteria: clinically overt type 2 diabe-
tes for at least 2 years, treated by diet or oral glucose‐lowering 
medication alone (no previous insulin use), free from micro‐ 
and macrovascular complications except for background 
retinopathy and haemoglobin A1c (HbA1c) levels below 
75 mmol/mol (9.0%). Healthy obese participants met the 
following inclusion criteria: fasting glucose < 6.1 mmol/L, 
HbA1c < 42 mmol/mol (6%) and a normal glucose toler-
ance test (plasma glucose levels below 6.5 mmol/L 2 hours 
after a 75 mg glucose challenge). The study was approved by 
the Radboud University Medical Center institutional review 
board and has been performed in accordance with the ethical 
standards as laid down in the 1964 Declaration of Helsinki 
and its later amendments. All participants provided written 
consent.
2.2 | Hyperinsulinaemic glucose clamps
All participants presented in the morning at 8.00 AM after an 
overnight fast (at least 8 hours). Participants with type 2 dia-
betes omitted their morning oral glucose‐lowering medica-
tion (if applicable). Upon arrival, two catheters were inserted 
intravenously. One catheter was placed into the antecubital 
vein for frequent blood sampling and was positioned in a 
heated box (55‐60ºC) to obtain arterialized venous blood. 
The second catheter was inserted in the antecubital vein of 
the contralateral arm for infusion of insulin (Insulin Aspart; 
Novo Nordisk) and glucose 20% w/w (Baxter). Subsequently, 
infusion of insulin was initiated at a rate of 120 mU per m2 
per min after a bolus of 1 U (referred to as time point 0). 
Plasma glucose levels were brought to predetermined levels 
using a variable infusion of glucose 20%, based on plasma 
glucose measured at 5‐minutes intervals (Biosen C‐line; 
EKF Diagnostics), which was sustained during infusion of 
[18F]FDG, the incubation time and the scan. At the start of 
the clamping procedure, when plasma glucose levels were 
within the euglycaemic range, and just prior to positioning 
the patient in the scanner, when plasma glucose levels were 
within the predetermined range, blood was drawn to deter-
mine levels of growth hormone, cortisol, epinephrine and 
norepinephrine.
2.3 | PET imaging with [18F]FDG
PET imaging was performed using a Siemens Biograph 
mCT‐40 time‐of‐flight PET/CT scanner. When stable 
plasma glucose levels were reached (targeting at 3.0 and 
5.0 mmol/L for hypoglycaemia and euglycaemia, respec-
tively), 1.6 MBq/kg [18F]FDG was infused. PET/CT images 
were obtained approximately 1 hour after injection from the 
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base of the skull until the knees at 4 minutes per bed posi-
tion. A low‐dose CT acquisition (40 mAs and 130 kV) of 
the same area as that covered by the PET scan was used 
for PET attenuation correction and as an anatomic refer-
ence. The size of the CT transaxial matrix was 512 × 512 
(0.98 × 0.98 mm), and the CT slice width was 3 mm. High 
definition reconstruction of the images was performed 
with three iterations, 21 subsets and a post‐reconstruction 
Gaussian filter of 3 mm in full width at half maximum. The 
transaxial PET matrix size was 256 × 256, and pixel size 
was 3.18 × 3.18 × 3.
2.4 | PET image tissue uptake quantification
PET/CT images were reviewed using Inveon Research 
Workplace software (version 4.1; Siemens Healthcare). 
CT images were smoothed with a Gaussian filter of 1 mm. 
Subsequently, regions of interest (ROIs) were drawn delin-
eating different tissues on the CT image. AT was deline-
ated by thresholding at −110 to −70 HU.6 The resulting 
ROI was then manually divided between visceral AT, ab-
dominal subcutaneous AT and gluteofemoral AT. Skeletal 
muscle was delineated by manually drawing ROIs around 
the upper legs, lower back and right shoulder and perform-
ing thresholding at −21 to 104 HU within these ROIs to de-
lineate skeletal muscle. ROIs around the liver and pancreas 
were drawn manually. All ROIs were drawn by a blinded 
observer. Tracer activity within the ROIs was recorded 
and expressed as standard uptake value (SUV), defined as 
activity per mL of tissue divided by the injected dose in 
MBq/g bodyweight.
2.5 | Statistical analysis
Data analysis was performed using SPSS (version 22; SPSS) 
with P < 0.05 considered statistically significant. Results are 
expressed as mean ± SD. Glucose infusion rates during the 
procedure were compared between the groups using a two‐way 
ANOVA repeated‐measures analysis. The effects of type 2 dia-
betes and hypoglycaemia were tested using one‐way ANOVA. 
Post hoc analyses were performed using the Bonferroni‐Dunn 
test to reveal statistically significant differences between the 
groups. Levels of hormones before and during the procedure 
were compared using a Wilcoxon signed rank test.
3 |  RESULTS
3.1 | Study participant characteristics
Table 1 shows the baseline characteristics of the participants. 
Patients with type 2 diabetes were generally well‐controlled 
and older than the two control groups, but well matched for 
BMI to the healthy obese participants.
3.2 | Plasma glucose levels 
during the clamps
During the clamping procedure, glucose levels were 
5.0 ± 0.3 mmol/L for the euglycaemia group. In the hypo-
glycaemia groups, glucose levels were 3.0 ± 0.1 for the 
healthy obese participants and 3.0 ± 0.1 for the patients with 
type 2 diabetes (P = NS, Figure 1A). Mean glucose infusion 
rates during the procedure were 7.1 ± 1.9 mg/kg/min for the 
 
Nondiabetic Type 2 diabetes
Euglycaemic 
clamp (n = 5)
Hypoglycaemic 
clamp (n = 5)
Hypoglycaemic 
clamp (n = 5)
Age (y) 30 ± 4 27 ± 6 60 ± 5
Sex (female:male) 2:3 4:1 0:5
Bodyweight (kg) 110 ± 8 89 ± 5 88 ± 4
BMI (kg/m2) 31.0 ± 1.1 30.0 ± 1.1 29.3 ± 0.4
Duration of diabetes (y) NA NA 11 ± 3
Diet   1
Oral medication
Metformin   3
Sulfonylurea   1
Fasting glucose (mmol/L) 4.86 ± 0.25 5.08 ± 0.12 7.86 ± 0.49
HbA1c (%)/(mmol/mol) 3.3 ± 0.1/ 3.2 ± 0.1/ 5.0 ± 0.2/
35.8 ± 0.9 34.8 ± 1.4 55.0 ± 2.1
Data are shown as means ± SD or as number (%).
T A B L E  1  Clinical characteristics of 
the study participants
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euglycaemia group. In the hypoglycaemia groups, glucose 
infusion rates were 4.0.0 ± 1.2 mg/kg/min for the healthy 
obese participants and 2.8 ± 1.0 mg/kg/min for the patients 
with type 2 diabetes (P = 0.023, Figure 1B).
3.3 | Counterregulatory hormones
For each group, levels of cortisol, growth hormone, epi-
nephrine and norepinephrine measured before the clamp-
ing procedure were compared to levels measured during the 
procedure, when stable blood glucose values were reached. 
Hypoglycaemia significantly stimulated the release of the 
counterregulatory hormones epinephrine, norepinephrine, 
cortisol and growth hormone, whereas plasma levels of these 
hormones did not change in response to euglycaemia (Table 
2). There were no major differences in these responses be-
tween subjects with type 2 diabetes and those without 
diabetes.
3.4 | The effect of hypoglycaemia on AT 
[18F]FDG uptake
The distribution of [18F]FDG was altered under hypogly-
caemic conditions compared to euglycaemic conditions in 
healthy obese individuals, with glucose uptake in visceral AT 
being significantly higher during hypoglycaemia (P = 0.004). 
Hypoglycaemia also caused a numerical increase in [18F]
FDG uptake in abdominal subcutaneous AT and gluteofemo-
ral subcutaneous AT, but this effect did not reach statistical 
significance (Figure 2A).
3.5 | Comparison of [18F]FDG uptake in AT 
between healthy participants and patients with 
type 2 diabetes
Under hypoglycaemic conditions, patients with type 2 diabe-
tes had a lower [18F]FDG uptake in visceral AT than the par-
ticipants without diabetes (Figure 2A, P < 0.0001). Patients 
with type 2 diabetes and healthy participants showed no sta-
tistically significant difference in [18F]FDG uptake either in 
abdominal subcutaneous AT or in gluteofemoral subcutane-
ous AT (Figure 2A). The total AT volume as well as the AT 
volume in the different depots did not differ significantly 
between the groups (data not shown, but available upon 
request).
3.6 | Comparison of [18F]FDG uptake 
between different AT depots and other organs
Uptake of [18F]FDG was compared between the differ-
ent AT depots. In all groups, [18F]FDG uptake in vis-
ceral AT was significantly higher than in subcutaneous 
AT. In healthy obese participants, visceral AT [18F]FDG 
uptake was approximately twice as high as abdominal 
F I G U R E  1  A, Time course of plasma 
glucose levels during the clamps. At time 
point 0, insulin infusion started. Black 
squares indicate values of the euglycaemia 
group. For hypoglycaemia: open circles, 
healthy participants; black triangles, type 
2 diabetic participants. B, Mean glucose 
infusion rates during the procedure. Data 
are shown as means ± SD. *P < 0.05 by 
Bonferroni‐Dunn test
T A B L E  2  Counterregulatory hormone levels before and during the clamping procedure
 
Healthy‐euglycaemia Healthy‐hypoglycaemia T2D‐hypoglycaemia
Before During Before During Before During
Growth hormone (mE/L) 8.5 ± 4.0 0.4 ± 0.2 19.1 ± 7.7 18.1 ± 7.3 3.1 ± 1.7 25.7 ± 9.4* 
Cortisol (µmol/L) 0.38 ± 0.04 0.25 ± 0.03 0.57 ± 0.18 0.53 ± 0.13 0.22 ± 0.02 0.47 ± 0.07* 
Epinephrine (nmol/L) 0.12 ± 0.02 0.11 ± 0.02 0.15 ± 0.04 1.15 ± 0.25* 0.13 ± 0.03 1.69 ± 0.74* 
Norepinephrine 
(nmol/L)
1.16 ± 0.10 1.19 ± 0.17 0.94 ± 0.13 1.24 ± 0.10* 1.28 ± 0.13 1.90 ± 0.26* 
Data are shown as mean ± SD
*P < 0.05 vs before values by Wilcoxon signed rank test. 
   | 5 of 7BOSS et al.
subcutaneous AT and gluteofemoral subcutaneous AT 
tracer uptake, both during euglycaemia (P < 0.0001) and 
during hypoglycaemia (P < 0.003). In patients with type 2 
diabetes, [18F]FDG in visceral AT was approximately 40% 
higher than in visceral subcutaneous AT and gluteofemoral 
subcutaneous AT (Figure 2A, P < 0.0001). Quantification 
of [18F]FDG accumulation in skeletal muscle, liver and 
pancreas did not reveal significant differences between the 
groups. However, because there was a numerically lower 
[18F]FDG uptake in skeletal muscle during hypoglycae-
mia, the tracer uptake ratio between AT and skeletal mus-
cle was 1:6.3 versus 1:3.2 in subjects under euglycaemic 
and hypoglycaemic conditions, respectively (P = 0.018, 
Figure 2A).
4 |  DISCUSSION
The main finding of this study is the stimulatory effect of 
hypoglycaemia on the uptake of [18F]FDG by AT. This 
method thereby enables a more precise and specific analy-
sis of glucose handling by both visceral and subcutaneous 
AT, which has been challenging so far because of the low 
uptake values in AT compared to skeletal muscle under 
nonhypoglycaemic conditions. By using this approach, we 
also showed that the uptake of glucose in visceral AT of 
patients with type 2 diabetes is about 40% lower than in 
BMI‐matched healthy participants (Figure 2), which sug-
gests a specific impairment in visceral AT metabolism in 
patients with type 2 diabetes.
[18F]FDG PET provides a tissue‐specific, noninva-
sive method for whole‐body analysis of glucose handling. 
Previous studies evaluating AT glucose metabolism using 
[18F]FDG PET were performed either under fasting condi-
tions without a clamping procedure or during a hyperinsu-
linaemic euglycaemic clamp.3-6,8,10 Under these conditions, 
uptake values of [18F]FDG in AT are low, especially com-
pared to uptake levels in skeletal muscle. Performing [18F]
FDG PET during a hyperinsulinaemic hypoglycaemic clamp 
significantly increased the tracer uptake in visceral AT of 
healthy participants and also resulted in a numerical increase 
in [18F]FDG uptake in subcutaneous AT. Since tracer uptake 
was not raised in skeletal muscle during hypoglycaemia, 
the uptake ratio between AT and skeletal muscle increased, 
allowing better discrimination (Figure 2A). We therefore 
propose that this method may provide a new, attractive re-
search tool that permits the comparison of glucose uptake in 
different AT depots and examination of glucose handling in 
patients with differences in metabolic health. This technique 
could potentially be valuable as a research tool to examine the 
underlying pathophysiology of patients at risk of developing 
type 2 diabetes.
While providing interesting methodological opportunities, 
it is not fully clear what causes the stimulatory effect of hy-
poglycaemia on visceral [18F]FDG uptake. Catecholamines, 
which increase in response to hypoglycaemia, suppress insu-
lin‐stimulated glucose uptake in skeletal muscle by activating 
protein kinase A through the stimulation of G‐protein cou-
pled receptors.11-13 In contrast, while the counterregulatory 
response to hypoglycaemia was shown to increase lipolysis 
rates in AT, insulin signalling seems to remain intact.14 This 
could provide a possible explanation for the increased uptake 
ratio between AT and skeletal muscle observed in this study. 
Another contributing factor could be activation of the en-
zyme 5’adenosine monophosphate‐activated protein kinase 
(AMPK) in adipocytes. AMPK is activated by metabolic 
F I G U R E  2  Uptake of 18F‐FDG 
in different AT depots and other organs 
(A) across the groups. Bars represent 
means ± SEM. *P < 0.05 by Bonferroni‐
Dunn test. [18F]FDG uptake ratios between 
AT and skeletal muscle are 1:6.3 and 
1:3.2 for subjects under euglycaemic and 
hypoglycaemic conditions, respectively. 
Representative PET images of healthy 
participants under euglycaemia and 
hypoglycaemia and type 2 diabetes patients 
under hypoglycaemia (B). Yellow arrows 
indicate visceral AT, and red arrows indicate 
abdominal subcutaneous AT
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stresses that inhibit ATP production, like hypoglycaemia.15 
This can in turn result in an increase of glucose uptake by 
adipocytes.16-18
By performing [18F]FDG PET during a hyperinsulinae-
mic hypoglycaemic clamp, we found a specific impairment 
in visceral AT metabolism in patients with type 2 diabetes 
compared to BMI‐matched, healthy participants. In subcuta-
neous AT depots, skeletal muscle, liver and pancreas, no sig-
nificant differences in [18F]FDG uptake were found between 
healthy and type 2 diabetic participants (Figure 2A). Also, 
in line with previous literature,4-6,8,10 the uptake of glucose 
was found to be significantly higher in visceral AT than in 
subcutaneous AT (Figure 2A), which can be explained by 
greater abundance and metabolic activity of visceral AT adi-
pocytes.10,19 Because of the tissue specificity of the observed 
impairment in [18F]FDG uptake in this study, combined with 
the glucose handling capacity of visceral AT, we hypothe-
size that visceral AT glucose handling could play a role in 
the pathophysiology of type 2 diabetes. Following this pilot 
study, future investigations with larger patient numbers are 
key to further substantiate this hypothesis. Also, in this study, 
static PET scans were performed one hour after the injection 
of the radiopharmaceutical to quantify the tissue‐specific up-
take of [18F]FDG. Future studies with dynamic PET could 
give insight into uptake kinetics and provide further infor-
mation on systemic glucose metabolism and its role in type 
2 diabetes.
The mechanism behind the observed impairment in 
visceral AT remains unclear. A possible explanation is a 
loss of visceral AT insulin sensitivity in type 2 diabetes, 
which is supported by clear mechanistic evidence for AT 
insulin resistance.7 However, differences in glucose up-
take by AT between healthy and type 2 diabetic subjects 
have not been found during euglycaemia in previous stud-
ies.4,8 Metabolic effects of counterregulatory hormones 
could also play a role. Cortisol and growth hormone, 
which were increased significantly in participants with 
type 2 diabetes during hypoglycaemia, while remaining 
stable in healthy participants (Table 2), are known to re-
press glucose uptake in AT.20,21 However, basal levels of 
these hormones were also higher in healthy participants. 
Also, effects of these hormones would not become acutely 
apparent,22,23 making their influence on the observed 
differences in this study less likely. Norepinephrine is 
known to increase the metabolic activity of adipose tis-
sue via beta3‐adrenergic receptors. Levels of norepineph-
rine were slightly increased in participants with type 2 
diabetes as compared to healthy participants. While this 
effect is generally described for brown adipose tissue, a 
deficiency in the beta3‐adrenergic pathway could poten-
tially contribute to the observed impairment in [18F]FDG 
uptake in VAT of participants with type 2 diabetes in this 
study.
Limitations of this study that should be considered are the 
inequality in age and gender between the participants with 
type 2 diabetes and the healthy participants. However, it has 
been reported that age alone does not significantly influence 
insulin sensitivity.24 Furthermore, uptake of [18F]FDG in AT 
has been shown to increase with age,25 which would merely 
mask the decrease in [18F]FDG uptake in AT of type 2 dia-
betes patients observed in this study. Also, there is no report 
on any influence of gender on biodistribution of [18F]FDG. 
We therefore do not expect the inequality in age and gender 
between the groups to affect the validity of these results.
In conclusion, the present data indicate that [18F]FDG 
PET/CT performed during a hyperinsulinaemic hypoglycae-
mic clamp could be a promising new research tool to exam-
ine AT metabolism. By using this method, we here show that 
[18F]FDG uptake during hypoglycaemia is impaired in type 
2 diabetes patients, specifically in visceral AT. This study 
thereby suggests a role for AT glucose handling in the patho-
physiology of type 2 diabetes.
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